Drugs in the Pipeline
Oral JAK/SYK Inhibitor Granted Fast Track Designation for Atopic Dermatitis
The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational oral dual inhibitor, ASN002 (Asana BioSciences), for the treatment of moderate-to-severe atopic dermatitis.